

### **Biopharmaceuticals Investor & Analyst Day**

Merck KGaA, Darmstadt, Germany – financial perspective on value creation Marcus Kuhnert CFO

Merck KGaA Darmstadt · Germany

Darmstadt, Germany – September 18, 2014



Disclaimer Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.

To reflect such fact and to avoid any misconception of the reader of the publication certain logos, terms and business descriptions of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada.



#### **Disclaimer**

#### Remarks

All comparative figures relate to the corresponding last year's period.

#### Important information

This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States. The shares referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from such registration.

Clinical candidates and early-stage products are currently under clinical investigation and have not been approved for use in the United States (US), Europe, Canada or elsewhere. The clinical candidates have not been proven to be safe or effective, and any claims of safety and effectiveness can be made only after regulatory review of the data and approval of the labeled claims.

#### Note regarding forward-looking statements

The information in this document may contain "forward-looking statements". Forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will" or words of similar meaning and include, but are not limited to, statements about the expected future business of Merck KGaA, Darmstadt, Germany. These statements are based on the current expectations of management of Merck KGaA, Darmstadt, Germany and E. Merck KG, Darmstadt, Germany and are inherently subject to uncertainties and changes in circumstances. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are changes in global, political, economic, business, competitive, market and regulatory forces. Merck KGaA, Darmstadt, Germany and E. Merck KG, Darmstadt, Germany do not undertake any obligation to update the content of this presentation and forward-looking statements to reflect actual results, or any change in events, conditions, assumptions or other factors.

All trademarks mentioned in the presentation are legally protected.




#### Agenda

Strong value creation since 2011

The road to 2018

Deep dive – Biopharmaceuticals


#### Strong increase in profitability and cash flow



#### Merck KGaA



### Share price development reflects good financial performance



### We have built a solid foundation for future growth



Consistent M&A strategy leading to an attractive portfolio

Expanded footprint in Emerging Markets

Good progress in cost management and restructuring

Optimized organizational model

Transformation of company culture on track









### Agenda


Strong value creation since 2011

#### The road to 2018

Deep dive – Biopharmaceuticals


### Strategic agenda beyond 2014 – Focus on growth

Merck KGaA





#### Levers of value creation



#### Merck KGaA


## Focus on inorganic growth while sustaining organic momentum


		Organic growth trend*	Inorganic perspective
Biopharmaceutical	5	<ul> <li>Emerging Markets growth</li> <li>Rebif pressure</li> <li>"Innovation" as potential upside</li> </ul>	<ul> <li>Biopharma valuations very high</li> <li>High risk from early stage and one-product calls</li> </ul>
Consumer Health		<ul> <li>Driven by strong brands and high EM exposure</li> </ul>	<ul> <li>Focus on potential bolt-ons</li> <li>Current transaction multiples not value accretive to our company</li> </ul>
Performance Materials		<ul> <li>Rising demand for consumer electronics</li> <li>Technology leadership</li> </ul>	<ul> <li>First priority on integration of AZ</li> <li>Small bolt-ons to add interesting technologies</li> </ul>
Life Science	263	<ul> <li>Resilient portfolio and sustainable market drivers</li> </ul>	<ul> <li>Highly fragmented market with consolidation potential</li> <li>Watch out: high valuations</li> </ul>

\*Short to mid-term

#### **Inorganic growth: Criteria for resource allocation**








- Commitment to earn cost of capital
- Immediately EPS pre accretive
- Preserve investment-grade rating
- Swift deleveraging post acquisition




### Strong progress since 2012 but further room for efficiency improvements





## Ongoing efficiency initiatives to reduce costs and to support our growth strategy



### Foster company culture as an enabler for success



	Performance orientation	
wth	Setting ambitious targets	
Growth	<ul> <li>Holding people accountable</li> </ul>	
	<ul> <li>Differentiated compensation</li> </ul>	
Cost	Strong leadership	
<b>∞</b> ŏ	Fair and constructive feedback culture	
cture	Empower teams to drive change	
Structure	Execution-driven organization	
	External focus	
ure	The "enemy" is outside!	
Culture	<ul> <li>Foster benchmarking</li> </ul>	
	Continue open and transparent communication	



### Agenda


Strong value creation since 2011

The road to 2018

**Deep dive – Biopharmaceuticals** 

Merck KGaA


### Growth initiatives will balance rising Rebif pressure – 'Innovation projects' provide upside potential



Illustration; \* without pipeline contribution


Merck KGaA

## Cost discipline: R&D investments for promising innovation projects will not visibly impact bottom line



Illustration

## Portfolio management: Differentiating across diverse Merck KGaA business models





#### Agenda

Strong value creation since 2011

The road to 2018

Deep dive – Biopharmaceuticals



Growth	Shift focus to acquisitions – strategic fit and financial discipline are key		
Ongoing fficiencies	Lay the foundation for profitable growth and support M&A readiness and generation of synergies		
Cultural change	Continue the way towards a performance- oriented culture	and the second	
riorities & Timing	There is no long term without a short term – promise and deliver!		Her I

# Merck KGaA Darmstadt · Germany



### **Back-up information**

### Share price development reflects good financial performance, outpacing DAX and EU pharma peers



#### Relative share price performance versus DAX and EU pharma peers in % (2011 - Sept. 2014) 140% +123% 120% +106% 100% **-97%** +88% 80% +74% 60% +57% 40% ·39% 20% +17% 0% -20% -40% 30-Dec-10 30-Jun-11 31-Dec-11 30-Jun-12 31-Dec-12 31-Dec-13 30-Jun-14 30-Jun-13 Merck KGaA, Darmstadt, - Bayer GSK - Novarits -Novo Nordisk — Roche ----- Sanofi DAX Index Germany